Shape Therapeutics
7 articles with Shape Therapeutics
-
Shape Therapeutics to Present the Discovery of Muscle-Specific AAVs at the Jefferies 2021 Virtual Healthcare Conference
5/25/2021
Shape Therapeutics Inc., a biotechnology company developing breakthrough technologies to enable gene therapy for all, announced that Francois Vignealt, PhD, President and Chief Executive Officer, is scheduled to present virtually at the Jefferies 2021 Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:00 p.m. Eastern Time.
-
Shape Therapeutics Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
5/4/2021
Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, today announced two abstracts have been accepted for digital presentation at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, taking place virtually May 11-14, 2021.
-
Shape Therapeutics Welcomes Patrick Bigot as its Chief Business Officer
4/20/2021
Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer.
-
Shape Therapeutics to Highlight RNA Editing Technology Platform Advancements in Parkinson’s Disease and the Identification of Novel CNS-targeting AAV Variants at the J.P. Morgan 39th Annual Healthcare Conference
1/11/2021
Shape Therapeutics Inc. (ShapeTX), a next-generation RNA-targeting gene therapy company, announces today the upcoming company presentation at the J.P. Morgan 39th Annual Healthcare Conference by Francois Vigneault, PhD., President and Chief Executive Officer.
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Shape Therapeutics Announces Appointment of Gary Fortin as Chief Operating Officer
12/8/2020
Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the appointment of Gary Fortin as Chief Operating Officer (COO). Prior to joining ShapeTX, Dr. Fortin was Head of Business Strategy and Operations for the Severe Genetic Disease unit of bluebird bio (NASDAQ:BLUE), where he navigated a portfolio of gene therapy programs through
-
Shape Therapeutics Unveils AAVid™ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene Therapy
12/3/2020
Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the unveiling of the AAVidTM capsid discovery platform and results from its first AAV5 variant library in a non-human primate selection campaign.